Skip to main content
SpringerLink
Log in

Stevens–Johnson syndrome and toxic epidermal necrolysis: early recognition and prompt management may reduce mortality

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent a spectrum of life-threatening mucocutaneous reactions. SJS/TEN usually induced by drugs, with the structure of the drug and genetic profile of the patient playing important roles in the development, recovery and prognosis of the reaction. While there are currently no internationally accepted management guidelines for SJS/TEN, early recognition and prompt treatment are essential to improve patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16(6):475–93.

    Article  PubMed  Google Scholar 

  2. Knowles S, Shear NH. Clinical risk management of Stevens–Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Ther. 2009;22(5):441–51.

    Article  PubMed  Google Scholar 

  3. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.

    Article  CAS  PubMed  Google Scholar 

  4. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):e297–304.

    Article  PubMed  Google Scholar 

  5. Saka B, Barro-Traor F, Atadokpédé FA, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52(5):575–9.

    Article  PubMed  Google Scholar 

  6. Mulvey JM, Padowitz A, Lindley-Jones M, et al. Mycoplasma pneumoniae associated with Stevens Johnson syndrome. Anaesth Intensive Care. 2007;35(3):414–7.

    CAS  PubMed  Google Scholar 

  7. Chung WH, Shih SR, Chang CF, et al. Clinicopathologic analysis of coxsackievirus A6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013;208(12):1968–78.

    Article  CAS  PubMed  Google Scholar 

  8. Mockenhaupt M. The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7(6):803–13.

    Article  PubMed  Google Scholar 

  9. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–33.

    Article  CAS  PubMed  Google Scholar 

  10. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525–34.

    Article  PubMed  Google Scholar 

  12. Ciccacci C, Di Fusco D, Marazzi MC, et al. Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013;69(11):1909–16.

    Article  CAS  PubMed  Google Scholar 

  13. Weinand C, Xu W, Perbix W, et al. 27 years of a single burn centre experience with Stevens–Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. Burns. 2013;39(7):1449–55.

    Article  CAS  PubMed  Google Scholar 

  14. Dodiuk-Gad RP, Olteanu C, Hashimoto R, et al. Long-term emotional and physical complications of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [abstract]. In: 23rd World Congress of Dermatology, 2015.

  15. Morales ME, Purdue GF, Verity SM, et al. Ophthalmic manifestations of Stevens–Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol. 2010;150(4):505–10.

    Article  PubMed  Google Scholar 

  16. Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol. 2004;4(5):411–9.

    Article  CAS  PubMed  Google Scholar 

  17. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson Syndrome and toxic epidermal necrolysis: comparison with case–control analysis. Clin Pharmacol Ther. 2010;88(1):60–8.

    Article  CAS  PubMed  Google Scholar 

  18. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173.e1–13.

  19. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.

    Article  CAS  PubMed  Google Scholar 

  20. Valeyrie-Allanore L, Bastuji-Garin S, Guégan S, et al. Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol. 2013;68(2):e29–35.

    Article  PubMed  Google Scholar 

  21. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–7.

    Article  CAS  PubMed  Google Scholar 

  22. Mockenhaupt M. Stevens–Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;2014(33):10–6.

    Article  Google Scholar 

  23. Valeyrie-Allanore L, Ingen-Housz-Oro S, Chosidow O, et al. French referral center management of Stevens–Johnson syndrome/toxic epidermal necrolysis. Dermatol Sin. 2013;31(4):191–5.

    Article  Google Scholar 

  24. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs. 2005;65(15):2085–90.

    Article  CAS  PubMed  Google Scholar 

  25. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847–53.

    Article  CAS  PubMed  Google Scholar 

  26. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens–Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144–8.

    Article  CAS  PubMed  Google Scholar 

  27. Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278–83.

    Article  CAS  PubMed  Google Scholar 

  28. Dodiuk-Gad RP, Chung WH, Yang CH, et al. The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: focus on severe cutaneous adverse reactions. Drug Saf. 2014;37(6):459–64.

    Article  PubMed  Google Scholar 

  29. Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, et al. A systematic review of treatment of drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;18:e121–33.

    PubMed  Google Scholar 

  30. Paquet P, Piérard GE. Topical treatment options for drug-induced toxic epidermal necrolysis (TEN). Expert Opin Pharmacother. 2010;11(15):2447–58.

    Article  CAS  PubMed  Google Scholar 

  31. Abela C, Hartmann CE, De Leo A, et al. Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm. J Plast Reconstr Aesthet Surg. 2014;67(8):1026–32.

    Article  PubMed  Google Scholar 

  32. Tomlins PJ, Parulekar MV, Rauz S. “Triple-TEN” in the treatment of acute ocular complications from toxic epidermal necrolysis. Cornea. 2013;32(3):365–9.

    Article  PubMed  Google Scholar 

  33. Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens–Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011;4(2):81–5.

    PubMed  PubMed Central  Google Scholar 

  34. Dube N, Adewusi E, Summers R. Risk of nevirapine-associated Stevens–Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007–2012. S Afr Med J. 2013;103(5):322–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from the American Journal of Clinical Dermatology 2015;16(6):475–93 [1] by salaried/contracted employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Stevens–Johnson syndrome and toxic epidermal necrolysis: early recognition and prompt management may reduce mortality. Drugs Ther Perspect 32, 238–243 (2016). https://doi.org/10.1007/s40267-016-0294-5

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-016-0294-5

    Keywords

    Search

    Navigation